Compare Amgen, Inc. (AMGN) vs Enovix Corporation (ENVX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Enovix Corporation — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while Enovix Corporation trades at $5.17 (market cap $1.14B). The key difference: Amgen, Inc. is far larger — about 172× Enovix Corporation's market cap, and Amgen, Inc. pays a 2.77% dividend while Enovix Corporation pays none. Which is the better fit depends on your goals.
| AMGN | ENVX | |
|---|---|---|
Market Cap | $196.12B | $1.14B |
Sector | Health | Technology |
52-Week High | $388.16 | $15.93 |
52-Week Low | $271.18 | $4.84 |
Enterprise Value | $241.41B | $1.15B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
ENVX trades at $5.20, down 3.7% on the day, with a bearish technical signal from moving averages. The company reported Q1 2026 revenue above guidance and an EPS beat of -$0.14 versus -$0.15 expected, but net losses remain substantial at -$156.74M for 2025. Positive developments include the appointment of a former Apple operations leader as COO to scale manufacturing.
The outlook is mixed: strong analyst buy consensus (75%) and a $12.75 price target suggest significant upside, but high cash burn, negative margins, and persistent losses pose substantial execution risks. Investor sentiment hinges on successful production scaling and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Enovix Corporation
Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.
Read more on ENVX →
